IMAX Adds 13 Laser Systems with Showcase Cinemas, Bolstering UK/Europe Network
Read source articleWhat happened
IMAX announced an agreement with Showcase Cinemas for 13 new IMAX with Laser systems, including 12 in the UK and one additional European location, marking the largest UK deal in IMAX history. The partnership reignites a relationship following Showcase's acquisition by a group led by a former Cineworld CEO, signaling renewed exhibitor confidence in premium formats. This deal is a notable addition to ex-China signings, which management has been using to offset cancellations in Greater China, where backlog has fallen from 501 to 421 systems. However, the 13 systems are incremental relative to the overall backlog and will take time to convert to revenue, so the near-term financial impact is limited. The announcement does not change the fundamental picture of a WAIT rating driven by full valuation and unresolved China attrition, but it offers mild positive evidence that ex-China expansion is progressing.
Implication
The 13-location agreement adds to ex-China signing momentum, which management needs to replace canceled China backlog, but it is small relative to the 421-system backlog and may take years to convert to revenue. Investors should continue monitoring the 90-day checkpoints: backlog stabilization above 421 and trailing global share reclaiming 3.8% from the current 3.7%. The stock remains richly valued at 57.8x P/E and 18.8x EV/EBITDA, so this announcement alone is unlikely to justify a higher multiple. A positive re-rating would require sustained ex-China signings like this, plus evidence of share recovery and China attrition ending in upcoming filings. Until then, the risk-reward remains balanced, with a better entry point near $37 rather than the current price above $43.
Thesis delta
The Showcase agreement modestly strengthens the ex-China offset portion of the thesis by adding 13 laser systems to the pipeline, but it does not address the core issues of China backlog erosion or trailing global share still at 3.7%. The overall WAIT rating is unchanged; conviction edges slightly higher that ex-China growth can replace lost China signings, but the next earnings report remains the key catalyst.
Confidence
Medium